艾昆纬（IQVIA）：2026加拿大公共疫苗获取时效研究报告（英文版）（25页）.pdf

1、 2026.All rights reserved.IQVIA is a registered trademark of IQVIA Inc.in the United States,the European Union,and various other countries.Prepared by IQVIA CanadaReal World SolutionsNovember 12th,2025Time to Public Time to Public Vaccine Access Vaccine Access in Canadain CanadaFINAL REPORT 2025 Pfi

2、zer Canada ULC,unless otherwise indicated.This report was prepared by IQVIA Solutions Canada Inc.and commissioned and funded by Pfizer Canada ULC.The analysis is based on secondary research and incorporates IQVIA proprietary methodologies and analytical frameworks,which remain the intellectual prope

3、rty of IQVIA Solutions Canada Inc.Pfizer Canada ULC has authorized the publication of this report by IQVIA Solutions Canada Inc.on its website.Reproduction or distribution is subject to applicable contractual and legal restrictions.DISCLAIMER3Table of Contents1.Executive summary1.Executive summary2.

4、Project methodology3.Overview of findings4.Provincial dashboards5.Summary of results4This report investigated the time to access the first publicly funded program for 29 vaccine analogs in Canada,across seven vaccine-preventable diseases(VPDs)1.Quebec was assessed based on alignment with current rec

5、ommendations from CIQ.The remaining provinces were assessed based on alignment with current NACI recommendations.Report objectivesExecutive summaryLeverage secondary research to calculate the time to access the first publicly funded program(time to public program access;TTPA)for 29 routine vaccine a

6、nalogs in each provinceDetermine provincial alignment with current recommendations from the National Advisory Committee on Immunization(NACI)or the Comit sur limmunisation du Qubec(CIQ)1 across seven vaccine-preventable diseasesIdentify province-and disease-specific trends in vaccine coverage and NA